Compare DNUT & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNUT | VOR |
|---|---|---|
| Founded | 1937 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 585.5M | 755.7M |
| IPO Year | 2021 | 2021 |
| Metric | DNUT | VOR |
|---|---|---|
| Price | $3.32 | $15.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | $4.72 | ★ $45.44 |
| AVG Volume (30 Days) | ★ 1.8M | 1.2M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.05% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,522,616,000.00 | N/A |
| Revenue This Year | $0.55 | N/A |
| Revenue Next Year | $3.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.58 | $0.13 |
| 52 Week High | $5.73 | $49.95 |
| Indicator | DNUT | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 46.90 | 54.63 |
| Support Level | $3.17 | $11.38 |
| Resistance Level | $3.50 | $16.88 |
| Average True Range (ATR) | 0.16 | 1.62 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 36.34 | 52.41 |
Krispy Kreme Inc is a sweet-treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations world-wide. It derives maximum revenue from the U.S. segment.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.